v3.22.2.2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 310,821	$ 7,942,971
Prepaid expenses and other current assets	102,354	241,904
Total current assets	413,175	8,184,875
Property and equipment, net	2,501	2,840
Total assets	415,676	8,187,715
Current liabilities:
Accounts payable and accrued expenses	5,919,626	4,170,266
COMMITMENTS AND CONTINGENCIES (NOTE 8)
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 20,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.001 par value; 50,000,000 shares authorized; 21,094,264 issued and outstanding	21,094	21,094
Additional paid-in capital	45,811,769	45,538,156
Accumulated deficit	(51,334,134)	(41,455,148)
Accumulated other comprehensive loss	(2,679)	(86,653)
Total stockholders' equity (deficit)	(5,503,950)	4,017,449
Total liabilities and stockholders' equity (deficit)	$ 415,676	$ 8,187,715

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Scopus BioPharma Inc. 10-Q